Current drug design to target the Semaphorin/Neuropilin/Plexin complexes.

Fiche publication


Date publication

novembre 2016

Journal

Cell adhesion & migration

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BAGNARD Dominique


Tous les auteurs :
Meyer LA, Fritz J, Pierdant-Mancera M, Bagnard D

Résumé

The Semaphorin/Neuropilin/Plexin (SNP) complexes control a wide range of biological processes. Consistently, activity deregulation of these complexes is associated with many diseases. The increasing knowledge on SNP had in turn validated these molecular complexes as novel therapeutic targets. Targeting SNP activities by small molecules, antibodies and peptides or by soluble semaphorins have been proposed as new therapeutic approach. This review is focusing on the latest demonstration of this potential and discusses some of the key questions that need to be addressed before translating SNP targeting into clinically relevant approaches.

Référence

Cell Adh Migr. 2016 Nov;10(6):700-708